Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
NCT02617654 on ClinicalTrials.gov · last registry update 2020-11-05
A small phase 2 — 18 participants, against a typical 110. Completed September 2020. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Per-Ola Carlsson
- Sponsor type
- Other
- Enrollment
- 18
- Started
- 2015-11
- Primary completion
- 2020-09 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production
Conditions studied
Type 1 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.